"instanceType","versionIdentifier","uuid:ID","id","rationale"
"StudyVersion","2","79a3fd90-10b0-4b16-9b22-d509fabe8cdd","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
